Pacific Biosciences of California (NASDAQ: PACB) and ResMed (NYSE:RMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Pacific Biosciences of California and ResMed, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California 0 2 1 0 2.33
ResMed 4 4 3 0 1.91

Pacific Biosciences of California presently has a consensus target price of $6.27, indicating a potential upside of 128.71%. ResMed has a consensus target price of $65.83, indicating a potential downside of 22.56%. Given Pacific Biosciences of California’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than ResMed.

Profitability

This table compares Pacific Biosciences of California and ResMed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacific Biosciences of California -95.97% -97.50% -59.40%
ResMed 16.58% 21.53% 11.90%

Valuation and Earnings

This table compares Pacific Biosciences of California and ResMed’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacific Biosciences of California $90.71 million 3.51 -$74.37 million ($0.92) -2.98
ResMed $2.07 billion 5.84 $342.28 million $2.47 34.42

ResMed has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Dividends

ResMed pays an annual dividend of $1.40 per share and has a dividend yield of 1.6%. Pacific Biosciences of California does not pay a dividend. ResMed pays out 56.7% of its earnings in the form of a dividend.

Institutional & Insider Ownership

70.5% of Pacific Biosciences of California shares are held by institutional investors. Comparatively, 62.0% of ResMed shares are held by institutional investors. 17.8% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 1.8% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Pacific Biosciences of California has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Summary

ResMed beats Pacific Biosciences of California on 9 of the 15 factors compared between the two stocks.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

ResMed Company Profile

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company’s portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.